Cover Image
市場調查報告書

雙特異性蛋白激酶TTK:開發中產品分析

Dual Specificity Protein Kinase TTK (TTK Protein Kinase or Cancer/Testis Antigen 96 or Monopolar Spindle 1-Like 1 or EC 2.7.12.1) - Pipeline Review, H1 2016

出版商 Global Markets Direct 商品編碼 365792
出版日期 內容資訊 英文 39 Pages
訂單完成後即時交付
價格
Back to Top
雙特異性蛋白激酶TTK:開發中產品分析 Dual Specificity Protein Kinase TTK (TTK Protein Kinase or Cancer/Testis Antigen 96 or Monopolar Spindle 1-Like 1 or EC 2.7.12.1) - Pipeline Review, H1 2016
出版日期: 2016年06月30日 內容資訊: 英文 39 Pages
簡介

本報告提供以雙特異性蛋白激酶TTK為標的之治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您最新的新聞和發表,加上企業和研究機關開發中的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

雙特異性蛋白激酶TTK 概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:不同症狀

開發中產品概況

  • 初期階段的產品

企業開發中的產品

大學/機關開發中的產品

治療藥的評估

  • 單劑/並用治療藥的情況
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

治療藥的開發企業

  • Bayer AG
  • Les Laboratoires Servier SAS
  • Nerviano Medical Sciences S.r.l.
  • Netherlands Translational Research Center B.V.
  • Pfizer Inc.

藥物簡介

暫停中的計劃

開發中止的產品

主要消息及新聞稿

附錄

圖表

目錄
Product Code: GMDHC0266TDB

Summary

Global Markets Direct's, 'Dual Specificity Protein Kinase TTK (TTK Protein Kinase or Cancer/Testis Antigen 96 or Monopolar Spindle 1-Like 1 or EC 2.7.12.1) - Pipeline Review, H1 2016', provides in depth analysis on Dual Specificity Protein Kinase TTK (TTK Protein Kinase or Cancer/Testis Antigen 96 or Monopolar Spindle 1-Like 1 or EC 2.7.12.1) targeted pipeline therapeutics.

The report provides comprehensive information on the Dual Specificity Protein Kinase TTK (TTK Protein Kinase or Cancer/Testis Antigen 96 or Monopolar Spindle 1-Like 1 or EC 2.7.12.1), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Dual Specificity Protein Kinase TTK (TTK Protein Kinase or Cancer/Testis Antigen 96 or Monopolar Spindle 1-Like 1 or EC 2.7.12.1) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Dual Specificity Protein Kinase TTK (TTK Protein Kinase or Cancer/Testis Antigen 96 or Monopolar Spindle 1-Like 1 or EC 2.7.12.1)
  • The report reviews Dual Specificity Protein Kinase TTK (TTK Protein Kinase or Cancer/Testis Antigen 96 or Monopolar Spindle 1-Like 1 or EC 2.7.12.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Dual Specificity Protein Kinase TTK (TTK Protein Kinase or Cancer/Testis Antigen 96 or Monopolar Spindle 1-Like 1 or EC 2.7.12.1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Dual Specificity Protein Kinase TTK (TTK Protein Kinase or Cancer/Testis Antigen 96 or Monopolar Spindle 1-Like 1 or EC 2.7.12.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Dual Specificity Protein Kinase TTK (TTK Protein Kinase or Cancer/Testis Antigen 96 or Monopolar Spindle 1-Like 1 or EC 2.7.12.1) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Dual Specificity Protein Kinase TTK (TTK Protein Kinase or Cancer/Testis Antigen 96 or Monopolar Spindle 1-Like 1 or EC 2.7.12.1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Dual Specificity Protein Kinase TTK (TTK Protein Kinase or Cancer/Testis Antigen 96 or Monopolar Spindle 1-Like 1 or EC 2.7.12.1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Dual Specificity Protein Kinase TTK (TTK Protein Kinase or Cancer/Testis Antigen 96 or Monopolar Spindle 1-Like 1 or EC 2.7.12.1) Overview
  • Therapeutics Development
    • Dual Specificity Protein Kinase TTK (TTK Protein Kinase or Cancer/Testis Antigen 96 or Monopolar Spindle 1-Like 1 or EC 2.7.12.1) - Products under Development by Stage of Development
    • Dual Specificity Protein Kinase TTK (TTK Protein Kinase or Cancer/Testis Antigen 96 or Monopolar Spindle 1-Like 1 or EC 2.7.12.1) - Products under Development by Therapy Area
    • Dual Specificity Protein Kinase TTK (TTK Protein Kinase or Cancer/Testis Antigen 96 or Monopolar Spindle 1-Like 1 or EC 2.7.12.1) - Products under Development by Indication
  • Dual Specificity Protein Kinase TTK (TTK Protein Kinase or Cancer/Testis Antigen 96 or Monopolar Spindle 1-Like 1 or EC 2.7.12.1) - Pipeline Products Glance
  • Early Stage Products
    • Dual Specificity Protein Kinase TTK (TTK Protein Kinase or Cancer/Testis Antigen 96 or Monopolar Spindle 1-Like 1 or EC 2.7.12.1) - Products under Development by Companies
    • Dual Specificity Protein Kinase TTK (TTK Protein Kinase or Cancer/Testis Antigen 96 or Monopolar Spindle 1-Like 1 or EC 2.7.12.1) - Products under Development by Universities/Institutes
  • Dual Specificity Protein Kinase TTK (TTK Protein Kinase or Cancer/Testis Antigen 96 or Monopolar Spindle 1-Like 1 or EC 2.7.12.1) - Therapeutics Assessment
    • Assessment by Monotherapy/Combination Products
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Dual Specificity Protein Kinase TTK (TTK Protein Kinase or Cancer/Testis Antigen 96 or Monopolar Spindle 1-Like 1 or EC 2.7.12.1) - Companies Involved in Therapeutics Development
    • Bayer AG
    • Les Laboratoires Servier SAS
    • Nerviano Medical Sciences S.r.l.
    • Netherlands Translational Research Center B.V.
    • Pfizer Inc.
  • Dual Specificity Protein Kinase TTK (TTK Protein Kinase or Cancer/Testis Antigen 96 or Monopolar Spindle 1-Like 1 or EC 2.7.12.1) - Drug Profiles
    • BAY-1161909 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BAY-1217389 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CCT-271850 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CFI-402257 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NMSP-153 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NMSP-715 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NTRC-00660 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit Mps1 for Breast Cancer - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit TTK Protein Kinase for Solid Tumor - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Dual Specificity Protein Kinase TTK (TTK Protein Kinase or Cancer/Testis Antigen 96 or Monopolar Spindle 1-Like 1 or EC 2.7.12.1) - Dormant Projects
  • Dual Specificity Protein Kinase TTK (TTK Protein Kinase or Cancer/Testis Antigen 96 or Monopolar Spindle 1-Like 1 or EC 2.7.12.1) - Discontinued Products
  • Dual Specificity Protein Kinase TTK (TTK Protein Kinase or Cancer/Testis Antigen 96 or Monopolar Spindle 1-Like 1 or EC 2.7.12.1) - Featured News & Press Releases
    • Sep 24, 2015: Servier and Nerviano Medical Sciences announce the entry of S 81694, an MPS1 inhibitor, in a first in Human clinical trial
    • Oct 29, 2012: Nerviano Medical Sciences To Present Four Posters At 24th EORTC-NCI-AACR Symposium
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for, H1 2016
  • Number of Products under Development by Therapy Area, H1 2016
  • Number of Products under Development by Indication, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Products under Investigation by Universities/Institutes, H1 2016
  • Assessment by Monotherapy/Combination Products, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Pipeline by Bayer AG, H1 2016
  • Pipeline by Les Laboratoires Servier SAS, H1 2016
  • Pipeline by Nerviano Medical Sciences S.r.l., H1 2016
  • Pipeline by Netherlands Translational Research Center B.V., H1 2016
  • Pipeline by Pfizer Inc., H1 2016
  • Dormant Projects, H1 2016
  • Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for, H1 2016
  • Number of Products under Development by Indication, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy/Combination Products, H1 2016
  • Number of Products by Stage and Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
Back to Top